IRD

Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Wall Street analysts forecast IRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRD is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Opus Genetics Inc revenue for the last quarter amounts to 3.08M USD, decreased -20.38 % YoY.

Opus Genetics Inc. EPS for the last quarter amounts to -0.25 USD, decreased -13.79 % YoY.

Opus Genetics Inc (IRD) has 18 emplpoyees as of December 17 2025.

Today IRD has the market capitalization of 147.58M USD.